Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance

Abstract
Background: Insulin resistance (IR) and related metabolic disturbances are characterized by low levels of adiponectin. High molecular weight adiponectin (HMWA) is considered the active form of adiponectin and a better marker of IR than total adiponectin. The objective of this study is to compare the utility of total adiponectin, HMWA and the HMWA/total adiponectin index (SA index) for the identification of IR and related metabolic conditions.

Methods: A cross-sectional analysis was performed in a group of ambulatory subjects, aged 20 to 70 years, in Mexico City. Areas under the receiver operator characteristic (ROC) curve for total, HMWA and the SA index were plotted for the identification of metabolic disturbances. Sensitivity and specificity, positive and negative predictive values, and accuracy for the identification of IR were calculated.

Results: The study included 101 men and 168 women. The areas under the ROC curve for total and HMWA for the identification of IR (0.664 vs. 0.669, \( P = 0.74 \)), obesity (0.592 vs. 0.610, \( P = 0.32 \)), hypertriglyceridemia (0.661 vs. 0.671, \( P = 0.50 \)) and hypoalphalipoproteinemia (0.624 vs. 0.633, \( P = 0.58 \)) were similar. A total adiponectin level of 8.03 μg/ml was associated with a sensitivity of 57.6%, a specificity of 65.9%, a positive predictive value of 50.0%, a negative predictive value of 72.4%, and an accuracy of 62.7% for the diagnosis of IR. The corresponding figures for a HMWA value of 4.25 μg/dl were 59.6%, 67.1%, 51.8%, 73.7% and 64.2%.

The area under the ROC curve of the SA index for the identification of IR was 0.622 [95% CI 0.554-0.691], obesity 0.613 [95% CI 0.536-0.689], hypertriglyceridemia 0.616 [95% CI 0.549-0.683], and hypoalphalipoproteinemia 0.606 [95% CI 0.535-0.677].

Conclusions: Total adiponectin, HMWA and the SA index had similar utility for the identification of IR and metabolic disturbances.

Background
Adiponectin is a peptide hormone produced by adipose tissue, involved in glucose and lipid metabolism [1-4]. The high molecular weight form is considered the active fraction of adiponectin; for this reason it is considered a better marker of metabolic disturbances than total adiponectin [5-7].

The average plasma concentration of this hormone ranges between 5 and 10 μg/ml; levels vary according to sex, body fat distribution, and metabolic status [8]. Men have approximately 15% lower levels compared to women [9]. Adiponectin concentration is lower in obesity, specifically central obesity [10] and studies confirm that levels increase with weight loss [11]. Low adiponectin concentrations have also been registered in individuals with coronary artery disease [12]. Finally, persons with diabetes have lower concentrations of this hormone compared to non-diabetics; levels are also low in states of hyperinsulinemia and glucose intolerance. Moreover, when adjusting for weight and body fat percentage, insulin sensitivity...
is independently associated with the adiponectin concentration [13]. The quantification of insulin resistance is desirable in clinical practice since this metabolic state is a treatable precursor of diabetes mellitus [14]. Established direct methods to quantify insulin sensitivity, such as the hyperinsulinemic euglycemic clamp, are complex and time consuming. Surrogate indexes are available, but there are no universal cutoff points to define IR. Adiponectin may be a useful marker for insulin resistance and a variable that can integrate the abnormalities of the metabolic syndrome. As yet, few studies have determined the utility of adiponectin for this purpose. In addition, it is not known whether the high molecular weight form is superior in the evaluation of IR. The aim of this study is to evaluate the utility of total adiponectin, HMWA and the $S_A$ index for the identification of IR and metabolic disturbances in a Mexican population.

Methods

Participants

Ambulatory subjects aged 20 to 70 yr were recruited between March and July 2008 in Mexico City. The population consisted of medium-income healthy workers without a personal history of metabolic abnormalities. To avoid confounding factors known to affect plasma adiponectin concentration the following exclusion criteria were applied: fever (temperature \( \geq 38^\circ \text{C} \)), hospitalization in the previous two weeks, known diabetes, arterial hypertension, dyslipidemia, coronary heart disease or a condition with equivalent risk (carotid disease, peripheral artery disease, and aortic aneurysm), congestive heart failure, stroke, chronic renal disease, active hepatic disease, chronic diseases or any other acute or chronic inflammatory illness. These criteria were evaluated by a questionnaire and in the case of diabetes, renal insufficiency and hypertension by the measurement of fasting glucose, serum creatinine and blood pressure. Subjects were also excluded if they were on any medication known to affect the metabolic profile (anti-hypertensives, statins, fibrates, metformin, thiazolidinediones, and salicylic acid). The Ethics Committee approved the protocol and all participants gave written informed consent.

Study protocol

A questionnaire was administered to all participants; demographic data and medical history including smoking habit were obtained. Height, weight, waist circumference, and blood pressure were measured. Blood pressure was measured twice, after a 5 minute rest between measurements, and the average value was used for data analysis. Blood samples were collected after a 9 to 12-hour fasting period, centrifuged, and refrigerated at -70°C. All assays were carried out on serum samples (except for adiponectin that was measured in plasma) in the laboratory of the Department of Endocrinology and Metabolism. This laboratory is certified by the External Comparative Evaluation of Laboratories Program of the College of American Pathologists. Glucose was measured using the glucose oxidase method (Boehringer Mannheim, Germany), total cholesterol, and triglycerides were measured using an enzymatic method (Boehringer Mannheim, Germany), HDL-cholesterol was measured after precipitation using phosphotungstic acid and Mg²⁺, low density lipoprotein (LDL)-cholesterol concentration was estimated by the Friedewald formula, plasma insulin was determined by a MEIA assay (Abbott Laboratories), total adiponectin and HMWA concentrations were measured using commercial assays (Millipore, Mexico).

Briefly, the HMWA assay is a sandwich ELISA. Firstly the adiponectin molecule is captured by a monoclonal anti-adiponectin antibody coating the wells; secondly a polyclonal anti-adiponectin antibody binds to the captured molecules. Finally, a streptavidin-horseradish peroxidase conjugate binds to this complex. The enzyme activity is measured spectrophotometrically at 450 nm. Prior treatment of the plasma samples removes hexameric and trimeric adiponectin allowing for the specific measurement of HMWA.

Definitions

Obesity was defined as a BMI of at least 30 kg/m², hypertriglyceridemia was considered present with a triglyceride level \( \geq 150 \text{ mg/dl} \), hypoalphalipoproteinemia was defined as HDL-cholesterol \( < 40 \text{ mg/dl} \) in men and \( < 50 \text{ mg/dl} \) in women. IR was evaluated and considered present when either: 1) the homeostasis model assessment of insulin resistance (HOMA-IR) was \( \geq 2.5 \); 2) insulin sensitivity (HOMA2%S) estimated by the HOMA2 calculator v2.2 (Diabetes Trials Unit, University of Oxford) was \( < 75\% \), and 3) the triglyceride/HDL-cholesterol index was \( \geq 3 \). The MS was defined according to the National Education for Cholesterol Education Program’s Adult Treatment Panel III (ATP-III) and the International Diabetes Federation (IDF) criteria [15,16].

Statistics

Normally distributed data, identified using Kolmogorov-Smirnov test, were expressed as mean ± standard deviation (SD). Variables with a skewed distribution were reported as median [interquartile range] [IQR]. Differences between groups were analyzed with the U-Mann Whitney or Kruskal-Wallis tests. Spearman’s correlation coefficients were used to explore the association between total adiponectin, HMWA and $S_A$ index and IR estimations. ROC curves were plotted and comparisons of the area under the curve were performed as described by De Long et al. [17] using Stata version 10 (College Station, Texas, USA).
Results
The study included 269 individuals (101 men and 168 women). The mean age was 40.1 ± 9.46 years and the mean BMI was 27.7 ± 4.26 kg/m². The study population characteristics are shown in Table 1. Using the ATP-III definition, 28.6% of the study population fulfilled criteria for the MS. When using the IDF criteria the prevalence of the MS rose to 37.9%.

Plasma total adiponectin and HMWA levels in the study population
There was a close correlation between the concentration of total adiponectin and HMWA (r = 0.890, P < 0.001). There was also a moderate concordance between individuals with total and HMWA below and above percentile 50 (kappa = 0.732, P < 0.001).

Consistent with the results of previous studies [7,9], total adiponectin and HMWA levels were higher in women than in men (total adiponectin 9.49 [5.31] vs. 6.85 [2.78] μg/ml, P < 0.001, HMWA 5.7 [4.25] vs. 3.5 [2.65] μg/ml, P < 0.001). Thirty two participants (22.8% of women) were post-menopausal. Adiponectin and HMWA concentrations did not differ between pre and post-menopausal women (total adiponectin 9.5 [4.72] vs. 9.9 [6.48] μg/ml, P = 0.122, HMWA 5.7 [3.90] vs. 6.5 [6.10] μg/ml, P = 0.067). Total adiponectin and HMWA concentrations were lower in obese vs. non-obese individuals (total adiponectin 7.56 [3.63] vs. 8.7 [4.40] μg/ml, P = 0.028, HMWA 4.10 [2.82] vs. 5.00 [3.90] μg/ml, P = 0.008).

In addition, when comparing subjects with or without the MS the concentrations of total and HMWA were significantly lower in subjects who fulfilled MS criteria. When classifying the participants by gender, this difference was not significant for men (Table 2).

Concentration of total and HMWA levels associated with insulin resistance
We evaluated total and HMWA concentrations by insulin tertiles. Both forms of adiponectin decreased significantly across the three insulin tertiles (total adiponectin 9.77 [4.58] vs. 8.27 [4.42] vs. 7.15 [3.79] μg/ml, P < 0.001), HMWA 5.7 [4.45] vs. 4.6 [3.6] vs. 3.7 [2.85] μg/ml, P < 0.001) (Figure 1).

A significant correlation was found between total adiponectin and the surrogate markers for insulin resistance. An almost identical correlation was encountered between HMWA and these markers; however, the correlation was lower for the S_α index (Table 3).

Total and HMWA concentration were significantly lower in individuals with IR estimated using HOMA-IR, triglyceride/HDL-cholesterol index and HOMA2%S. When dividing the population by gender this difference remained significant for all the surrogates of IR except HOMA2%S in males (Table 4).

Utility of total adiponectin and HMWA for the identification of IR and metabolic disturbances
We plotted ROC curves to compare the utility of plasma total adiponectin level, HMWA and S_α index for the identification of IR and metabolic disturbances. The AUC for total adiponectin was not significantly different to that of HMWA for the identification of IR estimated by HOMA-IR (total adiponectin 0.664 [95% CI 0.597-0.732] vs. HMWA 0.669 [95% CI 0.603-0.735], P = 0.743), triglyceride/HDL-cholesterol index (total adiponectin 0.717 [95% CI 0.655-0.778] vs. HMWA 0.730 [95% CI 0.670-0.790], P

Table 1: Characteristics of the study population

|                  | Total (n = 269) | Men (n = 101) | Women (n = 168) | P     |
|------------------|----------------|--------------|----------------|-------|
| Age (yr)         | 40.1 ± 9.49    | 40.5 ± 10.15 | 39.9 ± 9.42    | 0.582 |
| Systolic pressure (mmHg) | 111.1 ± 15.13 | 115.2 ± 15.00 | 108.5 ± 14.30 | 0.001 |
| Diastolic pressure (mmHg) | 74.5 ± 11.55 | 77.7 ± 9.98  | 72.6 ± 11.84  | <0.001|
| BMI (kg/m²)      | 27.7 ± 4.26    | 27.7 ± 3.81  | 27.7 ± 4.72    | 0.465 |
| Glucose (mmol/liter) | 4.92 ± 1.00    | 4.93 ± 0.58  | 4.91 ± 1.30    | 0.088 |
| Triglycerides (mmol/liter) | 1.46 [0.77] | 1.61 [0.94] | 1.37 [0.81] | <0.001|
| Cholesterol (mmol/liter) | 5.20 [1.42] | 5.12 [1.61] | 5.21 [1.44] | 0.987 |
| HDL-c (mmol/liter) | 1.16 [0.36] | 1.01 [0.28] | 1.21 [0.44] | <0.001|
| LDL-c (mmol/liter) | 3.34 [1.08] | 3.36 [1.20] | 3.32 [1.05] | 0.850 |
| Insulin (pmol/liter) | 65.28 [40.97] | 68.75 [45.83] | 63.19 [39.44] | 0.180 |

Values are means ± SD, or median [IQR]. Number of subjects in each group is indicated in parentheses.
In addition, the area under the ROC curves for total adiponectin and HMWA were not significantly different for the identification of metabolic abnormalities; obesity (total adiponectin 0.592 [95% CI 0.510-0.673] vs. HMWA 0.610 [95% CI 0.531-0.690], \( P = 0.32 \)); hypertriglyceridemia (total adiponectin 0.661 [95% CI 0.596-0.726] vs. HMWA 0.671 [95% CI 0.607-0.736], \( P = 0.504 \)); and hyperalphalipoproteinemia (total adiponectin 0.624 [95% CI 0.555-0.692] vs. HMWA 0.633 [95% CI 0.564-0.702], \( P = 0.582 \)).

The utility of the \( S_A \) index for the identification of IR and related metabolic disturbances showed an inferior performance compared with total adiponectin and HMWA concentrations; for IR estimated by HOMA-IR, total adiponectin 0.622 [95% CI 0.554-0.691], triglyceride/HDL-cholesterol index 0.663 [95% CI 0.598-0.729], and HOMA2%S 0.603 [95% CI 0.535-0.671]. The areas under the ROC curves were also lower for the identification of metabolic abnormalities; obesity 0.613 [95% CI 0.536-0.689], hypertriglyceridemia 0.616 [95% CI 0.549-0.683], and hypoalphalipoproteinemia 0.606 [95% CI 0.535-0.677]. When we analyzed the population stratifying by gender, the resultant conclusions with respect to the areas under the ROC curves of adiponectin, HMWA and the \( S_A \) index were similar as those derived from the total population (Table 5).

A total adiponectin level of 8.03 μg/ml was associated with a sensitivity of 57.6%, a specificity of 65.9%, a positive predictive value of 50.0%, a negative predictive value of 72.4%, and an accuracy of 62.7% for the diagnosis of IR using the HOMA-IR index. The corresponding figures

---

**Table 2: Concentrations of total and HMWA in patients with and without the metabolic syndrome**

|                                      | Total adiponectin (μg/ml) | \( P \) | HMWA (μg/ml) | \( P \) |
|--------------------------------------|---------------------------|--------|-------------|--------|
| **ATP criteria**                     |                           |        |             |        |
| All (n = 269)                        |                           |        |             |        |
| Metabolic syndrome (n = 77)          | 7.26 [3.57]               | 0.006  | 4.10 [3.07] | 0.007  |
| No metabolic syndrome (n = 192)      | 8.91 [4.84]               |        | 5.05 [4.03] |        |
| Men (n = 101)                        |                           |        |             |        |
| Metabolic syndrome (n = 30)          | 6.44 [2.94]               | 0.183  | 3.25 [2.13] | 0.245  |
| No metabolic syndrome (n = 71)       | 7.32 [2.65]               |        | 3.50 [3.00] |        |
| Women (n = 168)                      |                           |        |             |        |
| Metabolic syndrome (n = 47)          | 8.68 [4.58]               | 0.024  | 4.60 [5.00] | 0.037  |
| No metabolic syndrome (n = 121)      | 10.06 [4.91]              |        | 5.80 [4.20] |        |
| **IDF criteria**                     |                           |        |             |        |
| All (n = 269)                        |                           |        |             |        |
| Metabolic syndrome (n = 102)         | 7.27 [3.39]               | < 0.001| 3.95 [2.48] | < 0.001|
| No metabolic syndrome (n = 167)      | 9.11 [4.98]               |        | 5.40 [4.40] |        |
| Men (n = 101)                        |                           |        |             |        |
| Metabolic syndrome (n = 45)          | 6.68 [2.79]               | 0.123  | 3.20 [1.80] | 0.114  |
| No metabolic syndrome (n = 56)       | 7.52 [2.93]               |        | 3.55 [3.48] |        |
| Women (n = 168)                      |                           |        |             |        |
| Metabolic syndrome (n = 57)          | 8.68 [4.33]               | 0.002  | 4.60 [4.55] | 0.007  |
| No metabolic syndrome (n = 111)      | 10.48 [4.71]              |        | 6.20 [4.40] |        |

Values are medians [IQR]. Number of subjects in each group is indicated in parentheses.
for a HMWA level of 4.25 μg/dl were 59.6%, 67.1%, 51.8%, 73.7% and 64.2%, respectively. When using the triglyceride/HDL-cholesterol index, the sensitivity of a total adiponectin level of 7.76 μg/ml was 54.5%, specificity 80.5%, positive predictive value 79.4%, negative predictive value 56.2%, and accuracy 65.4%. The corresponding figures for a HMWA level of 4.65 μg/ml were 64.7%, 73.5%, 77.1%, 60.1%, and 68.4%, respectively. Finally, when considering the HOMA2%S value, a total adiponectin value of 8.25 μg/ml yielded a sensitivity of 52.4%, specificity 59.9%, positive predictive value 53.3%, negative predictive value 59%, and accuracy of 56.3%. The corresponding figures for a HMWA level of 4.25 μg/ml were 52%, 66.3%, 75.4%, 41.0%, and 56.7%.

**Discussion**

In recent years, several markers have been proposed for the screening, diagnosis, and therapeutic monitoring of insulin resistant patients [18]. However, all have problems that limit their use to research studies [19]. Not one succeeds in integrating the global assessment of the metabolic abnormalities that may increase the risk for developing type 2 diabetes and cardiovascular outcomes. Adiponectin is a promising biomarker of insulin resistance. Low adiponectin levels are associated with the majority of the metabolic syndrome traits and are related to an increased risk for having type 2 diabetes [20,21]. This hormone is not prone to degradation and is only minimally affected by diurnal variations, pre- vs. post-prandial status, and acute infections. Adiponectin levels can be assessed by either of three variables: total adiponectin, HMWA and the SA index. Here, we compare the diagnostic properties of these variables for detecting insulin resistance (assessed using surrogate markers) and other metabolic abnormalities in a population composed of apparently healthy adults. Total adiponectin, HMWA and the S_A index. Here, we compare the diagnostic properties of these variables for detecting insulin resistance (assessed using surrogate markers) and other metabolic abnormalities in a population composed of apparently healthy adults. Total adiponectin, HMWA and the S_A index had similar utility for the identification of the metabolic abnormalities. Our results suggest that

**Table 3: Correlation between total adiponectin, HMWA and S_A index and estimators of IR**

|                      | Adiponectin | High Molecular Weight Adiponectin | HMWA/adiponectin |
|----------------------|-------------|----------------------------------|------------------|
|                      | p           | p                                | p                |
| Fasting insulin      | -0.330      | 0.001                            | -0.323           | 0.001                  | -0.230 | 0.001   |
| HOMA-IR              | -0.332      | 0.001                            | -0.325           | 0.040                  | -0.228 | 0.001   |
| HOMA2S               | -0.329      | 0.001                            | -0.323           | 0.001                  | -0.231 | 0.001   |
| Triglyceride/HDL cholesterol | -0.458 | 0.001                             | -0.459           | 0.001                  | -0.302 | 0.001   |

HOMA-IR: homeostasis model assessment of insulin resistance
HOMA2S: insulin sensitivity estimated by the HOMA2 calculator v2.2 (Diabetes Trials Unit, University of Oxford)
### Table 4: Concentrations of total and HMWA in patients with and without insulin resistance

|                | Total adiponectin (μg/ml) |     | HMWA (μg/ml) |     |
|----------------|---------------------------|-----|-------------|-----|
|                |                           | P   |             | P   |
| **HOMA-IR**    |                           |     |             |     |
| All (n = 269)  |                           |     |             |     |
| Insulin resistance (n = 100) | 7.05 [3.70] | < 0.001 | 3.70 [2.90] | < 0.001 |
| No insulin resistance (n = 169) | 8.96 [4.78] |     | 5.30 [4.50] |     |
| Men (n = 101)  |                           |     |             |     |
| Insulin resistance (n = 42)  | 6.20 [3.15] | 0.049 | 3.15 [2.43] | 0.046 |
| No insulin resistance (n = 59) | 7.34 [2.65] |     | 3.80 [2.80] |     |
| Women (n = 168) |                           |     |             |     |
| Insulin resistance (n = 58)  | 8.73 [3.66] | < 0.001 | 4.70 [3.35] | < 0.001 |
| No insulin resistance (n = 110) | 10.76 [5.36] |     | 6.45 [4.58] |     |
| **Triglyceride/HDL-cholesterol** |                           |     |             |     |
| All (n = 269)  |                           |     |             |     |
| Insulin resistance (n = 156) | 9.90 [4.84] |     | 5.90 [4.20] |     |
| No insulin resistance (n = 113) |                           |     |             |     |
| Men (n = 101)  |                           |     |             |     |
| Insulin resistance (n = 78)  | 8.17 [2.98] | 0.024 | 3.20 [2.15] | 0.004 |
| No insulin resistance (n = 23) |                           |     |             |     |
| Women (n = 168) |                           |     |             |     |
| Insulin resistance (n = 78)  | 10.85 [4.73] | < 0.001 | 6.40 [4.43] |     |
| No insulin resistance (n = 90) |                           |     |             |     |
| **HOMA2%S**    |                           |     |             |     |
| All (n = 269)  |                           |     |             |     |
| Insulin resistance (n = 123) | 7.97 [3.74] | < 0.001 | 4.20 [3.23] | < 0.001 |
| No insulin resistance (n = 146) | 8.70 [4.74] |     | 4.95 [4.58] |     |
| Men (n = 101)  |                           |     |             |     |
| Insulin resistance (n = 47)  | 6.61 [3.28] | 0.115 | 3.20 [2.80] | 0.240 |
| No insulin resistance (n = 54) | 7.33 [2.71] |     | 3.55 [2.63] |     |
| Women (n = 168) |                           |     |             |     |
| Insulin resistance (n = 76)  | 9.01 [4.62] | 0.001 | 4.90 [3.70] | < 0.001 |
| No insulin resistance (n = 92) | 10.76 [5.15] |     | 6.55 [4.63] |     |

Values are medians [IQR]. Number of subjects in each group is indicated in parentheses.
plasma total adiponectin may provide clinical information of the same diagnostic value as HMWA. This finding may stimulate the use of adiponectin in clinical and epidemiological settings because the measurement of total adiponectin is better standardized, cheaper and more accessible than the other two approaches.

The highly significant correlation with insulin resistance makes adiponectin a powerful marker for diabetic risk. Several groups have shown that a low adiponectin level predicts the incidence of diabetes in children [22] and adults from several ethnic backgrounds [23]. Its high molecular weight form is the active fraction of adiponectin, is selectively down-regulated in IR states [5,14], and has been proposed as the best approach to evaluate adiponectin concentrations. However, the studies that support this conclusion have a small sample size [24], are

Figure 2 Area under the ROC curve of total and HMWA for the diagnosis of IR. A. Area under the ROC curve of total (0.664 [95% CI 0.597-0.732]) and HMWA (0.669 [95% CI 0.603-0.735]) for the identification of IR considering HOMA-IR. B. Area under ROC curve of total (0.717 [95% CI 0.655-0.778]) and HMWA (0.730 [95% CI 0.670-0.790]) for the identification of IR considering triglyceride/HDL-cholesterol index. C. Area under ROC curve of total (0.617 [95% CI 0.549-0.684]) and HMWA (0.623 [95% CI 0.556-0.690]) for the identification of IR considering HOMA2%S.
Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
http://www.cardiab.com/content/9/1/26
Page 8 of 10

post hoc analysis of studies designed for other purposes [25] or include biased populations (i.e. individuals with cardiovascular disease) [5]. For example, Basu et al. evaluated adiponectin complex distribution in 11 type 2 diabetic and 7 nondiabetic subjects. Total adiponectin was lower in the diabetic subjects primarily due to a reduction of HMWA [24]. However, the limited sample size of this study does not allow for the evaluation of adiponectin or HMWA as a diagnostic test for IR. Hara et al. reported that HMWA was better than total adiponectin for the detection of IR [5]. In this study, the population consisted of patients with diabetes or those who had had a coronary angiography. The authors estimated IR (by calculating the HOMA index) and they reported a greater area under the ROC curve for HMWA of 0.713 (95% CI 0.620-0.805) than that found for total adiponectin of 0.615 (95% CI 0.522-0.708, \( P = 0.016 \)). In our study we investigated the utility of total vs. HMWA for the identification of IR and related metabolic disturbances in an adult Mexican cohort. This population had no factors known to interfere with adiponectin concentrations. Our results showed a similar area under the ROC curve for both total adiponectin 0.664 [95% CI 0.597-0.732] and HMWA 0.669 [95% CI 0.603-0.735], \( P = 0.743 \). The same conclusion was reached for all surrogate markers of insulin resistance. We believe that our results differ from previous reports because of the characteristics of the population under study. Our study sample is representative of persons in whom a clinical indicator of IR is needed for early identification of diabetes risk.

In addition, no difference between the three approaches was found in the areas under the ROC curves

| Table 5: AUC of total and HMWA for the identification of IR and related metabolic abnormalities |
|-----------------------------------------------|---------------|---------------|
| All \((n = 269)\)                      | Women \((n = 168)\) | Men \((n = 101)\) |
| IR by HOMA-IR                           |                |               |
| Total adiponectin                       | 0.664 [0.597-0.732] | 0.705 [0.622-0.788] | 0.615 [0.501-0.729] |
| HMWA                                   | 0.669 [0.603-0.735] | 0.693 [0.608-0.777] | 0.617 [0.506-0.728] |
| \(S_A\) index                          | 0.622 [0.554-0.691] | 0.631 [0.541-0.721] | 0.584 [0.472-0.697] |
| IR by triglyceride/HDL-cholesterol index|                |               |
| Total adiponectin                       | 0.717 [0.655-0.778] | 0.670 [0.587-0.753] | 0.655 [0.530-0.779] |
| HMWA                                   | 0.730 [0.670-0.790] | 0.661 [0.579-0.744] | 0.696 [0.557-0.835] |
| \(S_A\) index                          | 0.663 [0.598-0.729] | 0.604 [0.518-0.690] | 0.592 [0.475-0.777] |
| IR by HOMA2%S                           |                |               |
| Total adiponectin                       | 0.617 [0.549-0.684] | 0.654 [0.569-0.738] | 0.591 [0.479-0.704] |
| HMWA                                   | 0.623 [0.556-0.690] | 0.664 [0.582-0.747] | 0.568 [0.456-0.680] |
| \(S_A\) index                          | 0.603 [0.535-0.671] | 0.657 [0.574-0.740] | 0.524 [0.411-0.638] |
| Obesity                                 |                |               |
| Total adiponectin                       | 0.592 [0.510-0.673] | 0.591 [0.485-0.697] | 0.633 [0.507-0.758] |
| HMWA                                   | 0.610 [0.531-0.690] | 0.608 [0.504-0.713] | 0.637 [0.519-0.756] |
| \(S_A\) index                          | 0.613 [0.536-0.689] | 0.607 [0.510-0.705] | 0.637 [0.518-0.756] |
| Hypertriglyceridemia                   |                |               |
| Total adiponectin                       | 0.661 [0.596-0.726] | 0.650 [0.561-0.738] | 0.550 [0.434-0.666] |
| HMWA                                   | 0.671 [0.607-0.736] | 0.634 [0.545-0.724] | 0.604 [0.488-0.720] |
| \(S_A\) index                          | 0.616 [0.549-0.683] | 0.572 [0.480-0.664] | 0.586 [0.471-0.701] |
| Hypoalphalipoproteinemia               |                |               |
| Total adiponectin                       | 0.624 [0.555-0.692] | 0.621 [0.535-0.707] | 0.672 [0.565-0.780] |
| HMWA                                   | 0.633 [0.564-0.702] | 0.631 [0.545-0.716] | 0.657 [0.538-0.776] |
| \(S_A\) index                          | 0.606 [0.535-0.677] | 0.604 [0.516-0.691] | 0.597 [0.473-0.721] |

Values are areas [95% confidence interval]. Number of subjects in each group is indicated in parentheses.
for the identification of other metabolic disturbances (obesity, hypertriglyceridemia, hyperphaliproteinemia and IR). These findings suggest that adiponectin is of value for the identification of IR and metabolic disturbances. If this turns out to be the case, adiponectin may be a marker for global metabolic status. For this reason we attempted to estimate an adiponectin threshold for the identification of IR. The cutoff points used had a reasonable sensitivity and specificity. Further studies are needed to assess the diagnostic performance of these cut-off points in other populations.

One of the disadvantages of adiponectin is that the assay for its measurement is not widely available and is expensive. In addition, the HMWA is even more expensive and difficult to implement compared to the total adiponectin method. However, adiponectin measurements may be useful in the future to identify patients at risk for metabolic alterations and to monitor treatment results.

The cross sectional design, the use of surrogate markers (instead of the euglucemic hyperinsulinemic clamp) to measure insulin action and a moderate sample size are the main limitations of our study.

Conclusions
In this study, total adiponectin was as useful as HMWA and the $S_0$ index in evaluating metabolic status. In addition, there was a similar association between total and HMWA in assessing IR and related metabolic abnormalities.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
PA-W, DC-R and CA-S participated in the design, interpretation of the study, analysis of the data, and review of the manuscript. RM and FG-P participated in the review of the manuscript. IC-B, OA-C and MN-L participated in the methodology of the study. All authors have read and approved the final manuscript.

Acknowledgements
We express our gratitude to the laboratory personnel of the Department of Endocrinology and Metabolism of the Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”.

Author Details
Departamento de Endocrinología y Metabolismo Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” 14000 México D.F., México

Received: 2 April 2010 Accepted: 23 June 2010
Published: 23 June 2010

References
1. Nakano Y, Toibe T, Choi-Miura NH, Mazada T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120:803-812.
2. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin. More than just another fat cell hormone? Diabetes Care 1996, 26:2442-2450.
3. Yauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsunoyama-Kasaoka N, Ezaki O, Akamatsu Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Toibe K, Nagai R, Kimura S, Tomita M, Fрогелл P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoprotein and obesity. Nat Med 2001, 7:941-946.
4. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007, 56:1198-1209.
5. Hara K, Honkomichi M, Yamada T, Yago H, Miyazato O, Ebirumah H, Imai Y, Nagai R, Kodawaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
6. Nakano Y, Tajima S, Yoshimi A, Akahama H, Tushima M, Tasokota T, Negoro T, Tomita M, Toibe T. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 2006, 47:1572-1582.
7. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayunagi K, Takebayashi K, Okuno T, Inoue T, Node K, Toibe T, Insukai T, Nakano Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2005, 55:1594-1596.
8. Salmeniemi U, Zacharova J, Ruotsiainen E, Vauhkonen I, Pihlajamaki J, Kainulainen S, Punnonen K, Laakso M. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2006, 91:2416-2423.
9. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
10. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramaniam A, Langfield C, Saad MF, Rotter JL, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007, 92:2665-2671.
11. Anta Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyakoa K, Kuriyama H, Hishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
12. Ouchi N, Kihara S, Anta Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:1473-1476.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tartaranni P. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 85:1930-1935.
14. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005, 54:333-339.
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
18. Ferrannini E, Mar A. How to measure insulin sensitivity. J Hypertens 1992, 10:955-906.
19. Maruyama R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-26.
20. Lindsay RS, Funahashi T, Hansen RL, Matsuzawa Y, Tanaka S, Tartaranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-8.
21. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakahama A, Kohno N. Decreased total and high molecular weight adiponectin are
independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006, 91:3873-7.
22. Cruz M, García-Macedo R, García-Valerio Y, Gutiérrez M, Medina-Navarro R, Duran G, Wacher N, Kumate J. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 2004, 27:1451-3.
23. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med 2006, 84:112-21.
24. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hiperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007, 56:2174-2177.
25. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.

doi: 10.1186/1475-2840-9-26
Cite this article as: Almeda-Valdes et al. Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance Cardiovascular Diabetology 2010, 9:26